Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842699 · ClinicalTrials.gov registry record
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
A clinical trial of Renal Transplantation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT00842699 is a study of Renal Transplantation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants, below the 45-participant average among 7 other Renal Transplantation trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00842699, a study of Renal Transplantation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
Conditions Studied
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00842699
The ClinicalTrials.gov registry entry for NCT00842699 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 45-participant average among 7 other Renal Transplantation trials with a reported enrollment target (11% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Transplantation appearing as the primary indexed condition, and to 0 interventions.
NCT00842699 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00842699 about?
NCT00842699 is a clinical study titled "Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab". The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
What is the current status of trial NCT00842699?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2011-03.
What conditions does trial NCT00842699 study?
This clinical trial studies the following conditions: Renal Transplantation.
Who is sponsoring clinical trial NCT00842699?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00842699 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TCD601 in de Novo Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Envarsus XR® in Adolescent Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Tolerance by Engaging Antigen During Cellular Homeostasis
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
COMPLETED · Phase 2
-
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.